Adhesion-Reducing Polypeptide for Surgical Tissue Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods to prevent or reduce adhesions, particularly postoperative abdominal adhesions, are ineffective and often lead to recurring complications such as bowel obstruction, chronic pain, and increased healthcare costs, with existing agents causing detrimental effects on bowel anastomotic healing.
Innovation Solution
A composition comprising a polypeptide with the sequence YARAAARQARAKALARQLGVAA, either alone or with a pharmaceutically acceptable carrier, is applied topically or parenterally to prevent or treat adhesions, potentially using a biomedical device with a heparin coating for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing adhesion prevention agents are used, then adhesion formation is reduced, but bowel anastomotic healing is impaired
Solution Approach 1:
The patent changes the molecular parameters of the antiadhesive agent by using a specific polypeptide sequence (YARAAARQARAKALARQLGVAA) with defined amino acid composition, molecular weight, and chemical properties. This specific parameter definition allows the agent to selectively inhibit adhesion while preserving bowel healing, resolving the contradiction between adhesion prevention and anastomotic healing.
Solution Approach 2:
The polypeptide acts as an intermediary substance that mediates between the conflicting needs of adhesion prevention and bowel healing. By introducing this specific molecular intermediary, the patent enables simultaneous achievement of both adhesion reduction and maintained healing, rather than choosing one over the other.
2Object-affected harmful factors
If surgery is performed to treat adhesions, then existing adhesions are removed, but new adhesions form recurringly
Solution Approach 1:
The patent applies the polypeptide agent before adhesion formation occurs (preoperatively or intraoperatively), preventing the harmful effect before it manifests. This preliminary action approach addresses the root cause rather than treating symptoms, providing long-lasting prevention that reduces the need for recurrent surgery.
Solution Approach 2:
The patent establishes continuous protection against adhesion formation through the polypeptide agent's sustained presence and activity in the peritoneal cavity. This continuous useful action maintains adhesion prevention over time, eliminating the recurring nature of adhesion problems that occurs with intermittent or surgical interventions.
3Object-affected harmful factors
If conventional adhesion treatment methods are used, then adhesion symptoms are managed, but healthcare costs increase
Solution Approach 1:
The patent employs a simple, cost-effective polypeptide agent that can be administered repeatedly at low cost. This disposable-like approach replaces expensive, complex surgical interventions and long-term monitoring, reducing overall healthcare resource consumption while maintaining effective adhesion management.
Data Source
AI summary
The described invention provides compositions and methods for treating or preventing adhesions in a subject in need thereof, the method comprising the step of (a) administering an adhesion-reducing amount of a composition comprising a polypeptide having the amino acid sequence YARAAARQ ARAKALARQLGV AA [SEQ ID NO: 1] or a functional equivalent thereof and a carrier. The methods are clinically useful for reducing formation of adhesions initially and for therapeutic treatment of existing scars.